Total patients recruited 

0

Patients with suspected or proven COVID-19

0

Patients with suspected or proven Influenza

0

Total paediatric patients

0

Active paediatric sites 

0

Active sites in Europe

EU numbers – updated 03 May 2024

blank

UK REMAP-CAP

A Randomised, Embedded, Multi-factorial, Adaptive Platform trial for Community-Acquired Pneumonia

The study

The Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) was conceived after the 2009 Influenza AH1N1 (“Swine flu”) outbreak. During that pandemic and previous ones, the research response has been largely absent. REMAP-CAP was set up as an Adaptive Platform Trial embedded in clinical care that allows multiple therapies to be evaluated at the same time under a master protocol. In Europe, the trial is currently running in 15 countries.

blank
Completed your training?

Fill in the form and we’ll send you… in a few days!

blank